The role of monoclonal antibodies in the treatment of lymphomas.

about

Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.

P2860

Q38205856-F7A64BCB-996D-4B36-A4F2-9F4B6AFE9255

P2860

The role of monoclonal antibodies in the treatment of lymphomas.

Item

http://www.wikidata.org/entity/Q38069595

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The role of monoclonal antibodies in the treatment of lymphomas.

@en

type

Item

label

The role of monoclonal antibodies in the treatment of lymphomas.

@en

prefLabel

The role of monoclonal antibodies in the treatment of lymphomas.

@en

P1476

The role of monoclonal antibodies in the treatment of lymphomas.

@en

P2093

Jack W Hsu

http://www.w3.org/2001/XMLSchema#string

Nam H Dang

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

P304

227-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2012.755172

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23265087

http://www.w3.org/2001/XMLSchema#string

The role of monoclonal antibodies in the treatment of lymphomas.

about

P2860

P2860

The role of monoclonal antibodies in the treatment of lymphomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698